Deregulation of this pathway is detected in over 70% of human BC cases [59], and it is a determinant signaling cascade involved in resistance to various targeted therapies [60], including trastuzumab treatment in HER2+ or endocrine treatment in ER+ BC [61]. Here, ERBB2 is linked to breast cancer.